Home News GSK, SK Bioscience to test COVID-19 vaccine against AstraZeneca shot
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

GSK, SK Bioscience to test COVID-19 vaccine against AstraZeneca shot

by maria gbaf

(Reuters) – Britain’s GSK and South Korea’s SK Bioscience said on Tuesday the drugmakers have begun a late-stage trial of their COVID-19 vaccine candidate to assess immune response when compared with AstraZeneca’s approved shot.

The trial will enrol around 4,000 candidates globally and test SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s vaccine booster following positive early-stage data https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=91& earlier this month.

Results from the GSK-SK study are expected in the first half next year, and the vaccine will be supplied worldwide through the World Health Organization-led vaccine sharing programme COVAX if approved, the companies said.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)

You may also like